ACADIA Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Catherine Owen Adams
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18CEO
Catherine Owen Adams (54 yo)
less than a year
Tenure
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & CFO | 3.2yrs | US$2.59m | 0.026% $ 733.3k | |
| Executive VP | 3yrs | US$2.62m | 0.031% $ 875.1k | |
| Consultant | less than a year | US$7.59m | 0.11% $ 3.1m | |
| CEO & Director | less than a year | no data | no data | |
| VP, Chief Accounting Officer & Corporate Controller | 4.3yrs | no data | 0.0086% $ 241.1k | |
| Executive VP and Head of Research & Development | less than a year | no data | no data | |
| Senior Vice President of Technical Development | 2yrs | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | 1.2yrs | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Senior VP & Head of Sales | 2.8yrs | no data | no data | |
| Senior VP & Chief People Officer | 2.8yrs | no data | no data | |
| Senior Vice President of New Product Planning & Strategy | no data | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: ACAD's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Independent Director | 16.5yrs | US$392.75k | 0.012% $ 337.9k | |
| Independent Director | 8.9yrs | US$377.75k | 0.062% $ 1.7m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 9yrs | US$387.75k | 0.015% $ 430.3k | |
| Independent Director | 9.7yrs | US$387.75k | 0.021% $ 581.2k | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 8.8yrs | US$387.75k | 0.015% $ 413.5k | |
| Independent Chairman of the Board | 11.8yrs | US$432.75k | 0.062% $ 1.7m | |
| Independent Director | 4.2yrs | US$377.75k | 0.014% $ 377.5k |
9.0yrs
Average Tenure
66yo
Average Age
Experienced Board: ACAD's board of directors are considered experienced (9 years average tenure).